Background. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel administered to treat patients with acute coronary syndrome (ACS) is still being used. However, despite the proven efficacy of this treatment regimen, thromboembolic complications have been observed in some individuals. The reason for this phenomenon is linked to the so-called increased responsiveness of platelets despite high platelet resistance (HPR). A significant role in HPR is attributed to genetically determined differences in the absorption and activation of clopidogrel.
Introduction
Dual antiplatel therapy (DAPT) with aspirin and clopidogrel has until recently been the gold standard for the treatment of acute coronary syndrome (ACS) patients. Nevertheless, despite the proven efficacy of this treatment regimen, thromboembolic complications continue to be observed in some patients. 1, 2 The reason for this phenomenon is associated with a so-called sustained increase in platelets activity, in spite of DAPT. This phenomenon may be due to an impaired aspirin response, but it is mainly associated with an ineffective treatment with clopidogrel.
A number of factors contribute to increased platelet reactivity. The lack of expected effects of DAPT is most likely due to non-compliance to treatment recommendations. However, the complexity of genetically conditioned absorption and activation of clopidogrel is also important. The action of clopidogrel is conditioned by the efficacy of the pro-drug conversion into its active form. This process largely depends on intestinal absorption and complex hepatic metabolism. The first step of clopidogrel activation takes place in the gastrointestinal tract. The ABCB1 gene expression product, P-GP (glycoprotein), plays a key role here. It is a membrane protein of the gastrointestinal tract, which acts to regulate xenobiotics concentrations in the human body, including clopidogrel. Spot mutations in the ABCB1 gene type C3435C> T, resulting in the emergence of mutation homozygotes (TT) or mutation heterozygotes (CT) in place of proper homozygotes (CC), imply (TT) increased P-GP activity. This activity causes an excessive rejection of clopidogrel, hindering its attainment of adequate plasma concentrations. The polymorphism of this gene has a negative influence on the clinical effects of clopidogrel treatment and may cause high platelet resistance (HPR). An even greater association with individual differences in response to clopidogrel treatment is attributed to cytochrome P450. Its proper functioning allows for the final conversion of clopidogrel to its active metabolite.
Genetic studies are particularly difficult due to the numerous polymorphisms in the genes encoding CYP. CYP2C19, CYP3A4/5 and CYP1A2 are the most well-studied genetic variants. CYP2C19 alleles of type *2-*8 are these that impair the metabolism of clopidogrel. It was observed that having even 1 allele of CYP2C19*2 was associated with worse prognosis in a long-term follow-up of myocardial infarction with respect to the incidence of subsequent myocardial infarction, stroke and death. There have also been more cases of stent thrombosis in these patients. 3, 4 The effect of the allele *17 in laboratory conditions is expressed by lower values for maximum platelet aggregation, better platelet inhibition and higher plasma concentrations of the active metabolite. 5 The clinical effect of increased transcriptional activity of this polymorphism was associated with more bleeding. There have been no significant benefits noticed in terms of ischemic events and stent thrombosis. 6 In our research work, we evaluated the prevalence of polymorphism of major absorption genes (ABCB1) and clopidogrel metabolism (CYPC19 *2, *3, *17) in patients treated with coronary angioplasty with stent implantation due to ACS.
Material and method
A total of 199 patients (133 males and 63 females), mean age 65.2 ±11.9 years, randomized to the prospective study, were hospitalized for acute myocardial infarction, including unstable angina, with non ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (ST-elevation MI). All patients engaged in the research were treated according to European Society of Cardiology (ESC) recommendations using coronary angioplasty with stent implantation. The study was approved by the appropriate research ethics committee, and all patients included in the study gave written informed consent. The basic demographic data of patients are presented in Table 1 .
Genetic research
In order to identify genetic polymorphism identification, genetic material was extracted from 200 μL of whole blood Using the ability of the DNA to bind under certain conditions with silica, centrifugation of the lysate was carried out in a mini column containing the silica membrane, which was then rinsed twice with washing buffer. Finally, the membrane was given a mini column elution buffer to recover the purified DNA. Amplified polymerase chain reaction (PCR) was the next step with the use of 4 pairs of specific primers, respectively for: CYP2C19*17 (-3402C> T), CYP2C19*3, ABCB1 (C3435C> T) 
Division into absorption and metabolic phenotypes
The study population was divided into the group of "good absorbers" (GA), which included the wild-type homozygote (CC), which lacked the C3435C> T spot mutation in the ABCB1 gene, and the "poor absorbers" group (PA), which included the mutation heterozygotes (CT) and mutation homozygotes (TT) of the ABCB1 gene.
Alleles that negatively affect clopidogrel metabolism (CYP2C *2, *3), and thus contribute to higher platelet reactivity in laboratory tests, have been assigned to the socalled loss-of-function (LoF) group. In contrast, alleles promoting the effects of clopidogrel (CYP2C *17), thus decreasing platelet aggregation, were given GoF (gain-offunction) name. For the purposes of the present work, patients were eligible for 2 metabolic groups, due to the polymorphism and the onset of the LoF or GoF allele:
-poor metabolizers (PM) -*2 or *3 carriers/non-*17 carriers -individuals with at least 1 LoF allele and no GoF allele;
-not poor metabolizers (NPM) -without the presence of any LoF allele (i.e., *2 and *3) and simultaneously having at least 1 GoF allele (i.e., *17) or patients without LoF (i.e., *2 and *3) and GoF (i.e., *17) or carriers simultaneously with both opposing alleles (*2 or *3 and simultaneously *17).
Patients with both PA and PM (PA + PM) phenotype were also isolated from the study group. The rest of the patients were referred to as not PA + PM.
Results
The basic demographic data of the study population is presented in Table 1 . The data is typical of the population with ischemic heart disease.
Genetic research
The incidence of ABCB1 polymorphism in the study group is shown in Fig. 1 . The largest percentage of subjects were heterozygous (57.9%). The minority of the patients were identified as wild-type homozygotes (CC). The incidence of CYP2C19 *2 gene polymorphism is shown in Fig. 2 . Most of the variants studied were patients with alleles coding for normal protein activity, but 26.1% of them had at least 1 mutation. No CYP2C19 *3 allele was observed in the study population to reduce the activity of clopidogrel metabolism. A relatively high percentage of heterozygotes and wild-type homozygotes in the CYP2C19*17 allele were found in the study group (Fig. 3 ).
Division into absorption and metabolic phenotypes
The incidence of clopidogrel GA and PA patients in the study population is shown in Fig. 4 . The majority of the group were PA. Figure 5 shows the percentages of individual metabolic phenotype in the study population. The relatively high proportion of patients (18%) was found to be PM patients. The simutaneous incidence of PA and PM phenotypes is shown in Fig. 6 . As many as 29 patients in the study group were members of this group.
Discussion
In this work, genetic testing was performed in a homogeneous ethnic group of patients with ACS. An important element of the study was the high homogeneity of the study group. Each of the 199 categorized patients was Caucasian, and 92% of the study group were residents of Lower Silesia. The occurrence of ABCB1 homozygous mutation polymorphism was demonstrated in 26.1% of the subjects (n = 52), which is comparable to the 27% of the carriers of the modified gene present within the large TRITON-TIMI 38 study, based on a population of nearly 3,000 patients. 7 Analyses concerning the variability of polymorphisms in various ethnic groups have revealed the prevalence of mutation homozygotes in the indigenous population of South America (27%), among Caucasians (20%) and Africans (13%). 8 The distribution of polymorphisms in ABCB1 genes in the present study (CC 16.0%, CT 57.9%, TT 26.1%) is almost identical to that observed in large, randomized, multicenter studies. The obtained data correlates well with the analysis of genotypes of healthy volunteers in West Pomerania 9 and are slightly different with regards to wild-type homozygotes and heterozygotes among ACS patients in the population of Warszawa (CC 28%, CT 51%, TT 21%). However, the homozygous mutations percentage is very alike in different groups, as demonstrated in the study by Śpiewak et al. 10 The incidence of particular polymorphisms of the CYP2C19 variant depends on the ethnic group under consideration. The differences apply to each of the alleles being analyzed.
One of the dysfunctional alleles, CYP2C19*2, has been found in the East Asian population in the amount of up to 55%. Among Africans, this polymorphism was observed in 40% of the subjects, and in the Caucasian population in Europe, the prevalence of CYP2C19 *2 was reported in 30% of the subjects. 11 In France, Collet et al. analyzed 259 patients with ACS episode. In their work, the wild-type homozygotes group of CYP2C19*1/*1 variant embraced 72% of the subjects, heterozygote *1/*2 25%, and mutation homozygote *2/*2 -only 2%. 4 Almost identical results were obtained in German and Portuguese populations, and only slightly different results -in Hungarian population. [12] [13] [14] As far as we know, the research on the prevalence of this polymorphism in the Polish population was conducted only once in a study by Malek et al. 15 The authors reported that wild-type homozygotes appear in 80% of the population, heterozygotes in 18% and mutation homozygotes in 2%. Our study has shown 73.9% of wild-type homozygotes, 24,6% of heterozygotes and 1,5% of mutation homozygotes; therefore, the data confirms the predecessors' observations. The CYP2C19 *3 allele frequencies tend to vary across human populations. Most often this polymorphism is observed in East Asia. The incidence of *1/*3 genotype was reported by Jeong et al. at the level of 11%. 16 In Africa and Europe, this allele is much less frequent and sporadically exceeds 1%. In the Italian population, this percentage was reported at 1.6% 17 and in Russian population at 0.3%. 18 In our group of 188 patients, there was no single CYP2C19*3 mutation. To the best of our knowledge, our study is the first work which investigates the incidence of the CYP2C19*3 allele in the Polish population. The results confirm poor inspection of the discussed allele in this part of Europe.
Recently, CYP2C19*17 allele has been the most frequently reported polymorphism. In Europe, the heterozygous form of CYP2C19*17 allelic variant can be found in 31.7% of the population on average and the mutation homozygous -in 4.2%. Thus, the differences concern populations all over Europe. In Germany, the incidence of at least 1 allele *17 was reported at the frequency of 41%, in France 20% and in Sweden 18%. 5, 6, 11 In Poland, Kurzawski et al. analyzed the distribution of these polymorphisms in a group of 125 patients and found allele *17 in 27.2% of patients. 20 Widespread dissemination of the allele polymorphism in Africa is rarely reported in literature, but some reports indicate a frequency similar to that of the Caucasian population. 21 The incidence of the allele *17 in the Japanese population is estimated at 1.3% 22 and Chinese at 4%. 5 In our study on CYP2C19*17 polymorphisms, a higher incidence of this allele (40.8% heterozygous individuals and 4% homozygotes) was found, compared to the study by Kurzawski et al. 9 Nevertheless, when results obtained in this study are compared with those from a large group of over 1,500 German patients, one will find them to be very similar. 6 They also correspond to the results of studies conducted and published in Poland by Kubica et al. 23 In the study, the prevalence of the phenotype absorption and metabolism was assessed for the first time in the Polish population. As many as 14.6% of patients showed a cumulative occurrence of the polymorphism of the investigated genes which condition the malabsorption of clopidogrel and its impaired metabolism. The use of clopidogrel in this group of patients may pose a particular risk of achieving an inadequate effect of the drug and, hence, the risk of thromboembolic complications with all clinical implications.
The reported variability in polymorphism frequency, with confirmation of increased platelet reactivity despite clopidogrel administration, is a serious clinical problem. The presence of these polymorphisms is an independent and contributing factor to HPR and thromboembolic complications following ACS. This data, confirming a relatively high level of penetration in the area of clopidogrel polymorphisms, should prompt Polish clinicians to recommend firstly the most recent antiplatelet drugs (ticagrelor or prasugrel), in spite of significantly higher costs of such pharmacotherapy for their patients.
